Capital Flow Monitor · Sponsors · CIK 1815624
GelMEDIX, Inc.
238 MAIN STREET, FIFTH FLOOR, CAMBRIDGE, MA, 02142 · 941-228-8711
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$2.5M
Sold
$747K
% sold
29.9%
Investors
5
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-04-30 | D/A ·current | 506(b) | $2.5M | $747K | 29.9% | 5 | EDGAR ↗ |
| 2026-01-08 | D/A | 506(b) | $542K | $542K | 100.0% | 5 | EDGAR ↗ |
| 2025-10-14 | D | 506(b) | $397K | $397K | 100.0% | 2 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Max Cotler — Executive Officer / Director, Cambridge, MA
- Nasim Annabi — Director, Cambridge, MA
-
Reza Dana — Director, Cambridge, MA
2 other raises
- Claris Biotherapeutics, Inc. $55.7M of $121.5M · 45.9%
- SightStream Biotherapeutics, Inc. $1.8M of $1.8M · 100.0%
- Michael Cima — Director, Cambridge, MA
- Parinaz Motamedy — Director, Cambridge, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.